{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:38:10Z","timestamp":1784191090370,"version":"3.55.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1097\/inf.0000000000000438","type":"journal-article","created":{"date-parts":[[2014,6,7]],"date-time":"2014-06-07T12:39:19Z","timestamp":1402144759000},"page":"1169-1176","source":"Crossref","is-referenced-by-count":31,"title":["Antibody Persistence After Primary and Booster Doses of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents"],"prefix":"10.1097","volume":"33","author":[{"given":"Roger","family":"Baxter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Reisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley L.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Percell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Odrljin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Dull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Smolenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 2","key":"R1-20-20210202","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: clinical presentation and sequelae.","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"issue":"RR-2","key":"R2-20-20210202","first-page":"1","article-title":"Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"R3-20-20210202","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease.","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"R4-20-20210202","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease.","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"R6-20-20210202","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1086\/599117","article-title":"V59P13 Study Group. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.","volume":"49","author":"Jackson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R7-20-20210202","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jpeds.2014.02.025","article-title":"Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.","volume":"164","author":"Baxter","year":"2014","journal-title":"J Pediatr"},{"key":"R8-20-20210202","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4161\/hv.6.11.12849","article-title":"Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo(R)) or Menactra(R) among healthy adolescents.","volume":"6","author":"Gill","year":"2010","journal-title":"Hum Vaccin"},{"key":"R9-20-20210202","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2007.29-c","article-title":"Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.","volume":"299","author":"Snape","year":"2008","journal-title":"JAMA"},{"key":"R10-20-20210202","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.4049\/jimmunol.180.4.2165","article-title":"The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response.","volume":"180","author":"Blanchard Rohner","year":"2008","journal-title":"J Immunol"},{"key":"R11-20-20210202","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1001\/jama.283.21.2795","article-title":"Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial.","volume":"283","author":"MacLennan","year":"2000","journal-title":"JAMA"},{"key":"R12-20-20210202","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","article-title":"Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine.","volume":"24","author":"Snape","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R13-20-20210202","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1136\/bmj.39563.545255.AE","article-title":"Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study.","volume":"336","author":"Snape","year":"2008","journal-title":"BMJ"},{"key":"R14-20-20210202","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1086\/508776","article-title":"Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization.","volume":"43","author":"Snape","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R15-20-20210202","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/j.ijid.2012.10.001","article-title":"Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT).","volume":"17","author":"Ostergaard","year":"2013","journal-title":"Int J Infect Dis"},{"key":"R16-20-20210202","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/CDLI.8.3.616-623.2001","article-title":"Importance of complement source in measuring meningococcal bactericidal titers.","volume":"8","author":"Santos","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"R17-20-20210202","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/CVI.00549-10","article-title":"Measurement of functional anti-meningococcal serogroup a activity using strain 3125 as the target strain for serum bactericidal assay.","volume":"18","author":"Poolman","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"R18-20-20210202","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/CVI.00068-09","article-title":"Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or AC polysaccharide vaccine in adults.","volume":"16","author":"Findlow","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"R19-20-20210202","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/j.vaccine.2013.03.036","article-title":"The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age.","volume":"31","author":"Blanchard-Rohner","year":"2013","journal-title":"Vaccine"},{"key":"R20-20-20210202","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1097\/INF.0b013e318279ac38","article-title":"Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.","volume":"32","author":"Jacobson","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R21-20-20210202","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/INF.0b013e31823dce5c","article-title":"Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.","volume":"31","author":"Klein","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R22-20-20210202","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1016\/j.vaccine.2012.03.080","article-title":"Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers.","volume":"30","author":"Klein","year":"2012","journal-title":"Vaccine"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000000438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:04:24Z","timestamp":1620954264000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201411000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000000438","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}